Overview

* Dyne Q3 net loss of $108 mln beats analyst expectations

* EPS for Q3 beats analyst estimates

* Company reaffirms cash runway into Q3 2027

Outlook

* Dyne expects topline data for z-rostudirsen in December 2025

* Company anticipates U.S. launch of z-rostudirsen in Q1 2027

* Dyne expects U.S. launch of z-basivarsen in Q1 2028

Result Drivers

* BREAKTHROUGH DESIGNATION - FDA granted Breakthrough Therapy Designation to z-rostudirsen for DMD, aiding potential accelerated approval

* CLINICAL TRIAL EXPANSION - Dyne expanded ACHIEVE trial sites in the U.S., expecting full enrollment in early Q2 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Beat -$0.76 -$0.84

(14

Analysts

)

Q3 Net Beat -$108.04 -$117.30

Income mln mln (11

Analysts

)

Q3 Basic -$0.76

EPS

Q3 $113.89

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Dyne Therapeutics Inc ( DYN ) is $38.00, about 43.4% above its November 4 closing price of $21.52

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)